Floatz logo

Fingolimod

Relapsing Remitting Multiple Sclerosis

TG Therapeutics, Inc.Small moleculePhase 4 / ApprovedActive
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Relapsing Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB

View all 50 →

Same molecule, other indications

Fingolimod is also rated in:

multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
cerebral degenerationDormant
BB
Indicative ·
65 / 100
View asset →
cognitive disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →